New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon?

被引:100
作者
Vidal Gine, Claudio [1 ]
Fornis Espinosa, Ivan [1 ]
Ventura Vilamala, Mireia [1 ]
机构
[1] Asociac Bienestar & Desarrollo, Barcelona 08012, Spain
关键词
new psychoactive substances; adulteration; controlled drugs; illegal market; ECSTASY MARKET; MEPHEDRONE; MDMA;
D O I
10.1002/dta.1610
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The use of new psychoactive substances (NPS) as adulterants has received little attention in the literature. In this paper, results from Energy Control's drug checking service documenting the use of NPS as adulterants of controlled drugs are presented, and some reflections about possible explanations for this new phenomenon, potential risks for users, and challenges that it poses are discussed. From 2009 to 2012, 24 NPS belonging to several chemical classes such as phenethylamines, substituted cathinones, tryptamines, and methoxetamine were identified in 173 samples believed to be MDMA, amphetamine, ketamine, cocaine, mescaline, or methamphetamine. The NPS adulterant most frequently observed was 2-(4-bromo-2,5-dimethoxyphenyl) ethanamine (2C-B) followed by 1-(4-fluorophenyl)propan-2-amine (4-FA). Sixty-nine different combinations of substances were detected: 20 involving a controlled drug combined with an NPS, and 49 involving one or more NPS that substituted the controlled drug. As these combinations could pose substantial risks to users, the need to improve knowledge about toxicity associated with these combinations, and the danger of these substances being incorporated into the products of illegal markets, are highlighted. Drug checking services and the European Union's early-warning system operated by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Europol can play an important role in reducing the harm associated with this phenomenon. Copyright (C) 2014 John Wiley & Sons, Ltd.
引用
收藏
页码:819 / 824
页数:6
相关论文
共 31 条
  • [1] [Anonymous], 2010, WORLD DRUG REP 2010
  • [2] [Anonymous], 2012, EUR JOINT REP NEW PS
  • [3] Barriuso M., 2004, USO KETAMINA PAIS VA
  • [4] 4-Methyl-amphetamine: a health threat for recreational amphetamine users
    Blanckaert, P.
    van Amsterdam, J. G. C.
    Brunt, T. M.
    van den Berg, J. D. J.
    Van Durme, F.
    Maudens, K.
    van Bussel, J. C. H.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2013, 27 (09) : 817 - 822
  • [5] mCPP: an undesired addition to the ecstasy market
    Bossong, M. G.
    Brunt, T. M.
    Van Dijk, J. P.
    Rigter, S. M.
    Hoek, J.
    Goldschmidt, H. M. J.
    Niesink, R. J. M.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2010, 24 (09) : 1395 - 1401
  • [6] Boulanger-Gobeil C., 2012, ANN EMERG MED, V60, P103
  • [7] Instability of the ecstasy market and a new kid on the block: mephedrone
    Brunt, Tibor M.
    Poortman, Anneke
    Niesink, Raymond J. M.
    van den Brink, Wim
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2011, 25 (11) : 1543 - 1547
  • [8] The Drug Information and Monitoring System (DIMS) in the Netherlands: Implementation, results, and international comparison
    Brunt, Tibor M.
    Niesink, Raymond J. M.
    [J]. DRUG TESTING AND ANALYSIS, 2011, 3 (09) : 621 - 634
  • [9] An analysis of cocaine powder in the Netherlands: content and health hazards due to adulterants
    Brunt, Tibor M.
    Rigter, Sander
    Hoek, Jani
    Vogels, Neeltje
    van Dijk, Peter
    Niesink, Raymond J. M.
    [J]. ADDICTION, 2009, 104 (05) : 798 - 805
  • [10] 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects
    Caudevilla-Galligo, Fernando
    Riba, Jordi
    Ventura, Mireia
    Gonzalez, Debora
    Farre, Magi
    Barbanoj, Manel J.
    Carlos Bouso, Jose
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2012, 26 (07) : 1026 - 1035